Clobetasol Propionate

  • #LGM Pharma is a Clobetasol Propionate CAS# 25122-46-7 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 25122-46-7
  • AHFC code:
  • Synonyms: 21-Chloro-9-fluoro-11-hydroxy-16-methyl-17-(1-oxopropoxy)pregna-1,4-diene-3,20-dione (11beta,16beta)-, 21-Chloro-9-fluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17-propionate, Butavate, CCI 4725, CGP 9555, Clobesol, Clobetasol 17-propionate, Clobetasol propionate, Clobetasol propionate (emollient), Clobetasol propionate gel, Clobetasolpropionate, Clobex, Cormax, Dermoval, Dermovate, Dermoxinale, EINECS 246-634-3, Embeline, Embeline E, GR 2/925, Luxiq, Olux, Olux E, Olux-E, Temovate, Temovate E, UNII-779619577M, Yugofin
  • ATC Code: D07AD01
  • Chemical Formula: C25-H32-Cl-F-O5
  • Molecular Weight: 466.97
  • Assay/Purity: Typically NLT 98%
  • DrugBank: APRD00876
  • SMILES: CCC(=O)O[C,,]1([C,H](C[C,,H]2[C,,]1(C[C,,H]([C,]3([C,H]2CCC4=CC(=O)C=C[C,,]43C)F)O)C)C)C(=O)CCl
  • InChl: 1S/C25H32ClFO5/c1-5-21(31)32-25(20(30)13-26)14(2)10-18-17-7-6-15-11-16(28)8-9-22(15,3)24(17,27)19(29)12-23(18,25)4/h8-9,11,14,17-19,29H,5-7,10,12-13H2,1-4H3/t14-,17-,18-,19-,22-,23-,24-,25-/m0/s1
  • PubChem: 32798
  • IUPAC: pregna-1,4-diene-3,20-dione, 21-chloro-9-fluoro-11-hydroxy-16-methyl-17-(1-oxopropoxy)-, (11β,16β)-

Additional Details

Indication:
For short-term topical treatment of the inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp.
Pharmacodynamics:
Like other topical corticosteroids, clobetasol has anti-inflammatory, antipruritic, and vasoconstrictive properties. It is a very high potency topical corticosteroid that should not be used with occlusive dressings. It is recommended that treatment should be limited to 2 consecutive weeks and therapy should be discontinued when adequate results have been achieved.
Mode of Action:
The precise mechanism of the antiinflammatory activity of topical steroids in the treatment of steroid-responsive dermatoses, in general, is uncertain. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. Initially, however, clobetasol, like other corticosteroids, bind to the glucocorticoid receptor, which complexes, enteres the cell nucleus and modifies genetic transcription (transrepression/transactivation).
Metabolism:
Metabolized, primarily in the liver, and then excreted by the kidneys.
Toxicity:
Oral LD50 in rat and mouse is >3000 mg/kg. Topically applied clobetasol can be absorbed in sufficient amounts to produce systemic effects. Symptoms of overdose include thinning of skin and suppression of adrenal cortex (decreased ability to respond to stress).
General Reference:
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization

 

  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials